Mylan Debt to Equity Ratio 2006-2019 | MYL

Current and historical debt to equity ratio values for Mylan (MYL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Mylan debt/equity for the three months ending March 31, 2019 was 1.20.
Mylan Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2019-03-31 $14.21B $11.89B 1.20
2018-12-31 $14.26B $12.17B 1.17
2018-09-30 $14.44B $12.07B 1.20
2018-06-30 $14.38B $12.21B 1.18
2018-03-31 $13.58B $13.18B 1.03
2017-12-31 $14.10B $13.31B 1.06
2017-09-30 $13.99B $13.29B 1.05
2017-06-30 $15.39B $12.83B 1.20
2017-03-31 $16.07B $11.66B 1.38
2016-12-31 $16.56B $11.12B 1.49
2016-09-30 $12.97B $11.83B 1.10
2016-06-30 $12.77B $10.33B 1.24
2016-03-31 $7.67B $10.28B 0.75
2015-12-31 $6.30B $9.77B 0.65
2015-09-30 $7.20B $9.82B 0.73
2015-06-30 $7.27B $9.57B 0.76
2015-03-31 $7.13B $9.09B 0.78
2014-12-31 $7.04B $3.28B 2.15
2014-09-30 $7.00B $3.41B 2.05
2014-06-30 $9.22B $3.35B 2.75
2014-03-31 $9.05B $3.19B 2.83
2013-12-31 $8.86B $2.96B 2.99
2013-09-30 $6.81B $3.23B 2.11
2013-06-30 $6.66B $2.95B 2.26
2013-03-31 $6.45B $2.89B 2.23
2012-12-31 $6.11B $3.36B 1.82
2012-09-30 $5.21B $3.62B 1.44
2012-06-30 $5.55B $3.20B 1.74
2012-03-31 $5.29B $3.78B 1.40
2011-12-31 $5.22B $3.51B 1.49
2011-09-30 $4.82B $3.49B 1.38
2011-06-30 $5.18B $3.88B 1.34
2011-03-31 $5.12B $3.92B 1.31
2010-12-31 $5.63B $3.62B 1.56
2010-09-30 $5.67B $3.54B 1.60
2010-06-30 $5.51B $2.98B 1.85
2010-03-31 $5.54B $3.18B 1.74
2009-12-31 $5.47B $3.14B 1.74
2009-09-30 $5.53B $3.07B 1.80
2009-06-30 $5.39B $2.91B 1.85
2009-03-31 $5.37B $2.65B 2.03
2008-12-31 $5.50B $2.79B 1.98
2008-09-30 $5.46B $2.98B 1.83
2008-06-30 $4.95B $3.13B 1.58
2008-03-31 $4.97B $3.16B 1.58
2007-12-31 $4.91B $3.40B 1.44
2007-09-30 $1.61B $1.89B 0.85
2007-06-30 $1.70B $1.73B 0.98
2007-03-31 $1.69B $1.65B 1.02
2006-12-31 $0.71B $1.10B 0.64
2006-09-30 $0.71B $0.96B 0.74
2006-06-30 $0.71B $0.87B 0.82
2006-03-31 $0.71B $0.79B 0.90
2005-12-31 $0.79B $0.76B 1.04
2005-09-30 $0.79B $0.83B 0.95
2005-06-30 $0.02B $1.88B 0.01
2005-03-31 $0.02B $1.85B 0.01
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $9.443B $11.434B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $42.880B 7.81
Teva Pharmaceutical Industries (TEVA) Israel $8.593B 3.37
Bausch Health Cos (BHC) Canada $8.382B 5.73
Dr Reddy's Laboratories (RDY) India $5.986B 22.39
Supernus Pharmaceuticals (SUPN) United States $1.616B 16.15
Voyager Therapeutics (VYGR) United States $1.021B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.971B 54.32
Homology Medicines (FIXX) United States $0.854B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.752B 1.12
Akorn (AKRX) United States $0.602B 0.00
CymaBay Therapeutics (CBAY) United States $0.486B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.441B 0.00
Assembly Biosciences (ASMB) United States $0.335B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.281B 0.00
Sol-Gel Technologies (SLGL) Israel $0.175B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.151B 0.00
Acasti Pharma (ACST) Canada $0.079B 0.00
Agile Therapeutics (AGRX) United States $0.063B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.055B 0.00
Teligent (TLGT) United States $0.035B 0.00
Evoke Pharma (EVOK) United States $0.014B 0.00
Aevi Genomic Medicine (GNMX) United States $0.013B 0.00